{"entity":{"id":"stephen-schuster","kind":"person","name":"Stephen J. Schuster","aka":[],"tldr":"Led JULIET, which brought tisagenlecleucel, the first CAR-T, to adults with relapsed large B-cell lymphoma.","summary":"Stephen Schuster led the first trial of CTL019 (tisagenlecleucel) in lymphoma and was principal investigator of JULIET, the global trial that won its approval for relapsed or refractory DLBCL, and of the follow-up studies showing durable five-year remissions. He directs the lymphoma programme at Penn and continues to lead trials of next-generation CAR-T and bispecific antibodies.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schuster%20SJ%5BAuthor%5D%20tisagenlecleucel"}],"tags":["lymphoma","car-t","cell-therapy"],"related":[],"cancers":["dlbcl","follicular-lymphoma"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-juliet-tisagenlecleucel-dlbcl-nejm-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Robert and Margarita Louis-Dreyfus Professor in CLL and Lymphoma, Abramson Cancer Center, University of Pennsylvania","institutionId":"penn-abramson","specialisms":["CAR T-cell therapy","Lymphoma","Chronic lymphocytic leukaemia","Cellular immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schuster%20SJ%5BAuthor%5D%20tisagenlecleucel"}],"papers":[{"title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma (JULIET)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1804980"},{"title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1708566"}],"orcid":"0000-0002-3376-8978"},"route":"/people/stephen-schuster/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"institution":[{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/"}],"paper":[{"id":"paper-juliet-tisagenlecleucel-dlbcl-nejm-2019","kind":"paper","name":"JULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma","route":"/key-papers/paper-juliet-tisagenlecleucel-dlbcl-nejm-2019/"}],"trial":[{"id":"juliet","kind":"trial","name":"JULIET","route":"/trials/juliet/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}]}}